A study exploring the use of magic mushrooms in Canada found that nearly 80% of respondents believe that psilocybin, the active ingredient in magic mushrooms, should be medically available for patients in distress. In addition, approximately two-thirds of Canadian respondents concur that psilocybin should be legally obtainable for those who need it.
Beyond just advocating for increased accessibility, an impressive 84.8 percent of respondents think that the public health system should cover the costs of such treatments. A majority of Canadians view psilocybin as a viable therapeutic alternative, especially for the alleviation of end-of-life distress.
[toc]
Key Findings:
- Inhabitants from Québec, Ontario, Alberta, and British Columbia view psilocybin as a legitimate medical solution for managing existential distress at the end of life.
- Magic mushrooms are perceived as a safe method for treating existential distress.
- Participants in two double-blind studies reported immediate and lasting benefits, with effects persisting for six months or even longer.
Exploring Existential Distress
Existential distress, also known as existential suffering, spiritual distress, and demoralization, comes into play when individuals are faced with their own mortality. Patients may experience feelings of helplessness, isolation, anxiety, and a loss of purpose. This type of distress is especially prevalent in patients with life-threatening diseases, potentially leading to thoughts of hastening death or even suicide.
Generally, those grappling with terminal illnesses or significant life changes are the ones who most frequently experience this form of distress. It significantly impacts their mental health and overall life quality.
Existential therapy aims to address issues such as anxiety, depression, grief, loneliness, apathy, despair, identity confusion, and feelings of purposelessness and existential fear. However, it may require multiple sessions and may not be effective for everyone.
The uncertainty surrounding the effectiveness of such therapy is a major reason why many individuals seek alternative treatments.
The Stance of Health Canada on Psilocybin as a Therapeutic Alternative
Over the last two decades, preliminary clinical trials have highlighted the potential advantages of psychedelic substances in treating complex mental health conditions. Specifically, psilocybin has demonstrated quick and sustained relief from existential stress in patients approaching the end of their lives.
In recognition of the promising effectiveness of these proposed hallucinogenic mushrooms, especially when conventional treatments are insufficient, Health Canada modified the Special Access Program in 2022. This revision permits healthcare professionals to apply for controlled substances for their patients.
Canadian Public’s Support for Psilocybin Access
A research featured in the Palliative Care Journal evaluates societal views on psilocybin-assisted therapy for end-of-life care. The data from the study includes:
| Methodology | Participation from 2,800 Canadians from Québec, Ontario, Alberta, and British Columbia. 19% of those had prior experience with psilocybin (15% in Québec, 26% in British Columbia). |
| Findings | 79.3% regard psilocybin-assisted therapy as a legitimate medical choice for treating end-of-life existential stress. 63.3% feel that psilocybin should be incorporated into medical treatment. 84.8% endorse the delivery of this therapy by the public health system. 44.2% believe healthcare professionals should administer the substance without the supervision of Health Canada. |
These outcomes align with surveys from Canada, England, and Australia. The researchers stressed that their study is distinctive since it focuses on the application of psychoactive substances for managing existential distress in end-of-life situations.
Causes for Canadian Endorsement of Psilocybin Utilization
An increasing population of Canadians are accepting the application of psilocybin for therapy, mainly due to conclusions from esteemed research institutions. Another influencing factor is the perceived safety of psilocybin mushrooms for mitigating existential stress. Participants across various studies have not reported severe negative health outcomes, such as multi-organ failure.
| Study | Method | Results |
| Johns Hopkins Study | 51 patients were administered a high dose of psilocybin and a low dose as an active placebo control | Immediate and long-lasting |
| The therapy’s effectiveness is largely due to the mystical experiences it induces, which often involve a profound sense of unity and deep emotional insights. These benefits can last up to six months or even longer. | ||
| New York University Trial | In this trial, 29 patients were randomly selected to receive either psilocybin or the active placebo drug, niacin. | The study’s outcomes were consistent with those of the Johns Hopkins study. Participants who received psilocybin reported psychological relief, along with an enhanced perspective on life and death. |
| BMC Palliative Care | The study aimed to understand palliative care professionals’ perception of existential distress and their views on psychedelic therapy as a treatment method. It involved interviews with nineteen participants, including 7 doctors, 4 active nurses, 4 chaplains, 3 social workers, and a psychologist. | Palliative care practitioners opined that psychedelic-assisted therapy (PAT) could potentially alleviate existential distress. |
Patient Experiences
Besides scientific studies, patient narratives also provide substantial evidence supporting the efficacy of psilocybin in promoting mental wellbeing and enhancing life quality.
Yokoi’s Experience
Mio Yokoi, a terminal stage 4 pancreatic cancer patient, describes a transformative experience during her assisted therapy. She envisioned being on a raft, surrounded by nature, and accompanied by whimsical creatures. This vision fostered a profound understanding of the universe’s interconnectedness and support, bringing her immense peace and affirmation.
Even with traditional mental health support, Yokoi struggled with severe anxiety and distress following her diagnosis. Psilocybin therapy reestablished her body connection and provided a tangible sense of love and support, significantly improving her emotional and mental health.
Chrissy’s Narrative
Chrissy, a healthcare administrative supervisor in her 50s, was diagnosed with stage 4 breast cancer, which had metastasized to her lungs. She identified as an atheist and was diagnosed with Generalized Anxiety Disorder during her screening.
Following her therapy, Chrissy reported significant reductions in anxiety, depression, fear of death, hopelessness, and demoralization. When asked about changes in her religious or spiritual beliefs post-therapy, she said the experiences had added depth and authenticity to her beliefs.
Brenda’s Narrative
Brenda, a lady in her sixties, was diagnosed with stage I colon cancer. During the examination, it was revealed that she had never consumed hallucinogens and she fit the criteria for Chronic Adjustment Disorder with accompanying Anxiety.
In the course of her therapy, Brenda had two near-death experiences. Despite this, she came out of the sessions with no fear of death, seeing it as a natural part of life. She attributed this significant shift in perspective and healing from childhood trauma to the study. Her data reflected this profound change.
Her fear of death and anxiety decreased, while her sense of spirituality increased.
Availability of Magic Mushroom Products in Canada
At present, the access to psilocybin capsules and related products for handling existential distress or other mental health conditions may be limited. However, reliable online dispensaries can provide these products when needed.
| Attribute | Brazilian Psilocybe Cubensis | Cambodian Psilocybe Cubensis | Melmac Psilocybe Cubensis |
| Origin | Native to Brazil and some surrounding South American countries. | Discovered in Cambodia, near the Angkor Wat Temple. | Associated with Penis Envy mushrooms, which became popular in the 1970s. |
| Potency | Moderately potent; suitable for beginners. | Moderately potent as well; perfect for novices. | Highly potent; advised for those with medium to high experience. |
| Effects | Triggers a mental stimulation, slight confusion, enhanced color perception, euphoria, spiritual experiences, increased creativity, and better focus. | Induces a long-lasting and energizing high, minor visual changes, increased creativity, euphoria, a gentle physical high, fractal images, and feelings of joy. | Provokes profound shamanic experiences, vision quests, intense mystical experiences, enhanced creativity, focus, social awareness, and mood improvement. |
Using Psilocybin Products to Ease End-of-life Discomfort
Existential or end-of-life distress can greatly affect many patients nearing the end of their life. Conventional treatments for this distress may not always be effective, leading to an increase in Canadian advocacy for easier access to magic mushrooms within the public healthcare system. This growing public interest could We advocate for the consideration of magic mushrooms as a potential treatment option by regulatory bodies. Obtain your psychedelics and mushroom delivery from Get Magic Mushrooms Canada.
Frequently Asked Questions
What should patients expect from Psilocybin-Assisted Therapy?
The experience of Psychedelic-assisted therapy (PAT) varies greatly from patient to patient. Ensuring a positive outcome requires careful preparation and strict adherence to certain procedures. Prior to consumption of the substance, patients must undergo rigorous screening and mental preparedness.
- Preparation before the Session: A thorough evaluation of the patient is performed. The therapist discusses the patient’s goals and expectations to set intentions for the session. The therapist also informs the patient about the potential effects and what to expect during the session.
- The Session: A controlled dosage of the substance is administered to the patients in a serene, distraction-free environment to promote relaxation and introspection. The therapist remains present throughout to provide continuous support and guidance.
- Post-Session Integration Therapy: This therapy helps the patient comprehend and process their experiences. Subsequent sessions provide continuous support and counselling to reinforce the insights and transformations achieved during therapy.
What effect does psilocybin have on the brains of distressed patients?
Psilocybin interacts with the brain by binding to serotonin receptors, particularly the 5-HT2A receptor. This interaction can trigger changes in perception, mood, and cognition, leading to significant alterations in consciousness, emotional breakthroughs, and new perspectives.
Is psilocybin therapy available to everyone?
Psilocybin therapy is not appropriate for everyone. Patients suffering from certain mental health conditions or existential distress are thoroughly screened to exclude those with a history of psychosis.
Related Articles:
